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http://dx.doi.org/10.1016/j.ccr.2012.06.014SUMMARYHere, we have investigated the role of the Notch pathway in the generation and maintenance of KrasG12V-
driven non-small cell lung carcinomas (NSCLCs). We demonstrate by genetic means that g-secretase and
RBPJ are essential for the formation of NSCLCs. Of importance, pharmacologic treatment of mice carrying
autochthonousNSCLCswith a g-secretase inhibitor (GSI) blocks cancer growth. Treated carcinomas present
reduced HES1 levels and reduced phosphorylated ERK without changes in phosphorylated MEK. Mechanis-
tically, we show that HES1 directly binds to and represses the promoter ofDUSP1, encoding a dual phospha-
tase that is active against phospho-ERK. Accordingly, GSI treatment upregulates DUSP1 and decreases
phospho-ERK. These data provide proof of the in vivo therapeutic potential of GSIs in primary NSCLCs.INTRODUCTION
Lung cancer is the leading cause of cancer-related deaths in the
world. A major challenge in treating lung cancer is to find novel
therapeutic targets that can complement current chemotherapy.
The Notch pathway is highly complex and regulates various
processes, such as embryonic development, cell fate decisions,Significance
NOTCH1 oncogenic mutations have been found in T cell leukem
activates AKT and NFkB through HES1-mediated transcripti
known, however, about how the Notch pathway participates in
either genetically or pharmacologically, hampers primary Kra
demonstrate that HES1 directly represses the promoter of D
activity against phospho-ERK. Treatment with GSIs induces D
phosphorylation, a critical player in NSCLCs. These results
NSCLCs.
222 Cancer Cell 22, 222–234, August 14, 2012 ª2012 Elsevier Inc.and tissue homeostasis, and it has been implicated in a variety of
human diseases, including cancer (Chiba, 2006; Demarest et al.,
2008; Ferrando, 2009; Hass et al., 2009; Roy et al., 2007). Briefly,
this pathway involves a total of five activatory ligands, four
NOTCH receptors, sequential proteolytic processing of the
ligand-bound receptors to generate active Notch intracellular
domains (NICDs), and formation of DNA-binding complexesias and lung cancer. In T cell leukemias, the Notch pathway
onal repression of PTEN and CYLD, respectively. Little is
lung cancer. Here, we show that Notch pathway inhibition,
sG12V-driven non-small cell lung carcinomas (NSCLCs). We
USP1, which encodes a dual-specificity phosphatase with
USP1 expression, and this is associated with loss of ERK
validate the potential of GSIs for the treatment of primary
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Figure 1. Activity of the Notch Pathway in Murine KrasG12V-Driven
NSCLC
(A) Analysis of g-secretase activity by detection of PSEN1-CTF, and analysis of
NOTCH1 activity by detection of NICD and HES1 by immunoblotting (normal
lung: each lane corresponds to a different control WT mouse; adenocarci-
nomas: each lane corresponds to a grade 4 tumor from a different mouse).
(B) Detection of HES1 in murine KrasG12V lung tumors. Representative
examples of grade 2 (adenoma) and grade 4 (adenocarcinoma) tumors stained
with hematoxylin and eosin (H&E, left) and HES1 (middle and right) at low
magnification (middle) or high magnification (right). Bars in the four leftmost
panels correspond to 100 mm. Bars in the two rightmost panels correspond
to 50 mm.
(C) Quantification of HES1 during lung tumorigenesis. The graph depicts the
percentage of HES1-positive nuclei (detected by IHC as in B) within tumors of
different grades (n = 5 for each tumor grade).
(D) Levels of Numb mRNA measured by qRT-PCR in WT mouse lungs (n = 4)
and grade 4 tumors (n = 4).
Values correspond to the average ± SEM. Statistical significance was deter-
mined by a two-tailed Student’s t test: *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S1.
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g-Secretase and Lung Cancerwith a number of DNA-binding partners, with RBPJ being the
most important and the one that defines the so-called ‘‘canon-
ical’’ Notch pathway (Chiba, 2006; Demarest et al., 2008;
Ferrando, 2009; Heitzler, 2010; Roy et al., 2007). In turn, NICD-
containing complexes activate the expression of a number of
effectors, including the transcriptional repressor HES1 (Sang
et al., 2010).
The g-secretase complex is essential for the Notch pathway
because it is responsible for the activation of NOTCH receptors
by proteolytic cleavage (Hass et al., 2009). This complex is
formed by the assembly of four protein subunits, namely, a pre-
senilin subunit (PSEN1 or PSEN2), nicastrin (NCSTN), APH1, and
PSNEN (Fraering, 2007). The proteolytic activity of the g-secre-
tase complex occurs within the PSEN subunit; however, each
of the four subunits is essential for the formation of a functional
g-secretase complex (Fraering, 2007). In this regard, we have
demonstrated that the combined deletion of the PSEN genes
Psen1 and Psen2 results in ablation of NOTCH1 activation in
T cells (Maraver et al., 2007). Additionally, small-molecule inhib-
itors that target the g-secretase complex (known as g-secretase
inhibitors [GSIs]) (Wolfe, 2009) phenocopy Notch pathway inhibi-
tion in mouse models (van Es et al., 2005; Wong et al., 2004).
The oncogenic role of the Notch pathway is well established in
T cell acute lymphoblastic leukemias (T-ALL), and NOTCH1 is
oncogenically mutated in 60% of leukemias (Ferrando, 2009).
Investigators have reported a number of alterations in the Notch
pathway in human non-small cell lung carcinomas (NSCLCs),
including NOTCH3 overexpression (Haruki et al., 2005); loss of
expression of NUMB (Westhoff et al., 2009), a negative regulator
of the Notch pathway; and activating mutations in NOTCH1
(Westhoff et al., 2009). Previous reports have demonstrated
that GSIs induce apoptosis in human lung cancer cells grown
in vitro (Chen et al., 2007; Eliasz et al., 2010; Westhoff et al.,
2009) and slow the growth of subcutaneous xenografts formed
by human lung cancer cells (Konishi et al., 2007; Luistro et al.,
2009; Paris et al., 2005). However, little is known about the
activity of GSIs in primary autochthonous NSCLCs in their
natural environment, or about the mechanisms by which GSIs
could exert their antitumoral effect on NSCLCs.
In mice, inducible genetic activation of a latent Kras onco-
genic allele in the lung initiates a stepwise tumorigenic process
that culminates in NSCLCs very similar to those found in hu-
mans, sharing a common histology (Guerra et al., 2003; Jackson
et al., 2001) and a common transcriptional profile (Sweet-
Cordero et al., 2005). Therefore, we used this mouse model to
analyze the effect of the Notch pathway on the development of
NSCLCs.
RESULTS
The Notch Pathway Is Hyperactive in Murine
KrasG12V-Driven NSCLC
The Notch pathway is hyperactive in a subset of human NSCLCs
(Westhoff et al., 2009). Therefore, we wanted to know whether
this is also the case for murineKrasG12V-driven adenocarcinoma,
which is a common type of NSCLC (Guerra et al., 2003). All of the
analyzedmurine NSCLCs presented significantly higher levels of
NICD and HES1 compared with normal lung (Figure 1A). To eval-
uate the levels of g-secretase, we measured the abundance ofthe active forms of PSEN1 and NCSTN. In the case of PSEN1,
assembly into the g-secretase complex is associated with
proteolytic cleavage (Fraering, 2007). We observed higher levels
of the carboxy-terminal fragment of PSEN1 (PSEN1-CTF)
in murine NSCLCs compared with normal lung (Figure 1A),
whereas the levels of Psen1mRNAwere unchanged (Figure S1A
available online). These results agree with a previous study using
human fibroblasts cultured in vitro, in which ectopic overexpres-
sion of oncogenic HRAS was found to increase PSEN1 protein
levels without affecting its mRNA levels (Weijzen et al., 2002).
In the case of NCSTN, its assembly into the g-secretase complex
is associated with glycosylation and slower electrophoretic
mobility (Edbauer et al., 2002). As in the case of PSEN1, we
also observed higher levels of mature NCSTN in murine NSCLCsCancer Cell 22, 222–234, August 14, 2012 ª2012 Elsevier Inc. 223
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Figure 2. PSEN1 and PSEN2 Are Needed for the Generation of
KrasG12V-Driven NSCLC
(A) Graph depicting the number and grade of tumors per animal. Lungs
from KrasV12/WT and KrasV12/PSKO mice were pathologically analyzed
5.5–7.5 months after adeno-Cre delivery. For each genotype, n = 9 mice.
(B) Percentage of mice carrying grade 4 (adenocarcinoma) tumors. For each
genotype, n = 9 mice.
Values correspond to the average ± SEM. Statistical significance was deter-
mined by a two-tailed Student’s t test (A) or by Fisher’s exact test (B): *p < 0.05.
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g-Secretase and Lung Cancer(Figure S1B). These observations indicate higher levels of func-
tional g-secretase complex in murine KrasG12V-driven NSCLCs.
To define the kinetics of Notch pathway activation during lung
tumorigenesis, we tested the expression of HES1 by immunohis-
tochemistry (IHC) in murine lesions at different stages, from
grade 1 to grade 4 (with grades 1–3 corresponding to adenomas,
and grade 4 to adenocarcinomas) (Jackson et al., 2005). We
observed a direct association between tumor grade and HES1
nuclear signal, which reached its maximum in grade 4 lesions
(adenocarcinomas; Figures 1B and 1C, and Figure S1C). As an
internal control, we also observed strong nuclear expression of
HES1 in murine bronchioles (Collins et al., 2004; Ito et al.,
2000; Morimoto et al., 2010; Tsao et al., 2009) (Figure S1C).
Finally, we found lower levels of expression ofNumbmRNA (Fig-
ure 1D), a negative regulator of the Notch pathway whose ex-
pression is also diminished in human NSCLCs (Westhoff et al.,
2009). Together, these data indicate that murine KrasG12V-driven
NSCLCs faithfully recapitulate the activation of the Notch path-
way reported in human NSCLCs, validating that this mouse
lung cancer model is appropriate for analyzing therapeutic strat-
egies and mechanisms related to the Notch pathway.
The g-SecretaseComplex Is Needed forKrasG12V-Driven
NSCLCs
To evaluate the relevance of the Notch pathway in lung tumori-
genesis, we combined a Cre-inducible KrasG12V oncogenic allele
(KrasLSLG12Vgeo) (Guerra et al., 2003) and Psen1f/f;Psen2/
alleles (i.e., Psen1 flanked by loxP sites excisable by Cre recom-
binase, and Psen2 null) (Saura et al., 2004), thus generating
compound Kras+/LSLG12Vgeo;Psen1f/f;Psen2/ animals. Mice
were treated with intratracheal delivery of adeno-Cre (for brevity,
we refer to the resulting lungs as KrasV12/PSKO). Control mice
(Kras+/LSLG12Vgeo;Psen1+/+;Psen2+/+) were derived from the
same set of crosses as the Kras+/LSLG12Vgeo;Psen1f/f;Psen2/
mice [for brevity, we refer to the adeno-Cre treated lungs as
KrasV12/wild-type (WT) lungs]. Mice were killed between 5.5
and 7.5 months post-adeno-Cre delivery, and lung tumors
were graded and quantified (Figure 2A). Most tumors in control
KrasV12/WT lungs had progressed to grades 3 and 4; however,
in the case of KrasV12/PSKO lungs, there was no progression
beyond grade 1 (Figure 2A). We also measured the percentage
of animals with at least one grade 4 tumor (i.e., adenocarci-
noma). Of importance, whereas 44% of KrasV12/WT lungs
presented adenocarcinomas, none of the KrasV12/PSKO lungs
developed NSCLCs (Figure 2B).
The Canonical Notch Pathway Is Needed
for KrasG12V-Driven NSCLCs
Having established the requirement of the g-secretase com-
plex for generating KrasG12V-driven NSCLCs, we wanted to test
directly the role of the canonical Notch pathway in this process.
To that end, we generated compound mice carrying the Cre-
inducible KrasG12V oncogenic allele in combination with a floxed
allele of Rbpj, Rbpjf/f (Tanigaki et al., 2002). These mice and their
corresponding controls (for brevity, termed KrasV12/RbpjKO
and KrasV12/WT, respectively) were treated by intratracheal
delivery of adeno-Cre. It should be noted that in this experiment,
the batch of adeno-Cre was more active than in the previous
experiment (see Experimental Procedures), and thus yielded224 Cancer Cell 22, 222–234, August 14, 2012 ª2012 Elsevier Inc.a higher number of tumors per mouse. As was the case for the
KrasV12/PSKO mice, in the KrasV12/RbpjKO mice, grade 4
tumors (adenocarcinomas) were absent 5.5–7.5 months post-
adeno-Cre delivery (Figures 3A and 3B). We wondered whether
the grade 3 tumors present in KrasV12/RbpjKO mice had actu-
ally deleted the Rbpj gene or, alternatively, were nondeleted
Rbpj-floxed tumors (‘‘escapers’’). To address this issue, we
microdissected grade 3 tumors (n = 3), and we observed that
all of themwere escapers (Figure S2). Taken together, the results
of our genetic analyses indicate that the Notch pathway is essen-
tial for NSCLC formation driven by KrasG12V.
Pharmacological Inhibition of g-Secretase Arrests
KrasG12V-Driven NSCLCs
Having demonstrated that g-secretase is highly relevant for lung
tumorigenesis, and that the Notch pathway is strongly active in
lung cancer, we conducted a preclinical assay to test the impact
of g-secretase inhibition on primary NSCLCs. Previous reports
demonstrated that small-molecule inhibitors of the g-secretase
pathway (generally known as GSIs) induce apoptosis in lung
cancer cells grown in vitro (Chen et al., 2007; Eliasz et al.,
2010; Westhoff et al., 2009) and slow the growth of subcuta-
neous xenografts formed by lung cancer cells (Konishi et al.,
2007; Luistro et al., 2009; Paris et al., 2005). However, nothing
is known about the impact of GSIs on autochthonous primary
NSCLCs, i.e., in their natural microenvironment. For this assay,
we used compound LSN-411575 (Wong et al., 2004). This
compound has been well validated in rodents (Best et al.,
2005; Wong et al., 2004) and is one of the most potent GSIs
(Wolfe, 2009). To test the therapeutic potential of LSN-411575
in NSCLCs, we used mice carrying the above-mentioned Cre-
inducible KrasG12V oncogenic allele (KrasLSLG12Vgeo) together
with a tamoxifen-inducible Cre systemically expressed under
the RNA polymerase II promoter (Guerra et al., 2003). These
mice develop a mixture of lung adenomas (grades 1–3) and
adenocarcinomas (grade 4) upon induction with tamoxifen. After
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Figure 3. The Canonical Notch Pathway Is Needed for the Genera-
tion of KrasG12V-Driven NSCLC
(A) Graph depicting the number and grade of tumors per animal. Lungs from
KrasV12/WT and KrasV12/RbpjKO mice were pathologically analyzed 5.5–
7.5 months after adeno-Cre delivery. For each genotype, n = 7 mice.
(B) Percentage of mice carrying grade 4 (adenocarcinoma) tumors. For each
genotype, n = 7 mice.
Values correspond to the average ± SEM. Statistical significance was deter-
mined by a two-tailed Student’s t test (A) or Fisher’s exact test (B): #p < 0.1;
*p < 0.05; ***p < 0.001.
See also Figure S2.
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g-Secretase and Lung Cancer6–8 months of the tamoxifen induction, we analyzed changes in
tumor size and tumor metabolism by X-ray computed tomog-
raphy (CT) and positron emission tomography (PET), respec-
tively. Tumors greater than 0.5 mm in diameter were detectable
by CT, but only those of grade 4 (i.e. adenocarcinomas) were
PET positive (Figures S3A–S3C). Again, this recapitulates the
human pathology, in which only malignant tumors are PET posi-
tive (Fischer et al., 2001; Gould et al., 2001). Mice carrying
KrasG12V-driven tumors periodically underwent PET/CT scans,
and those carrying at least one PET-positive tumor were
randomly allocated into two groups that were treated daily
by gavage with vehicle for 15 days or with 3 mg/kg of LSN-
411575 for 15 or 22 days.
Previous investigators reported deleterious side effects asso-
ciated with the use of GSIs, especially in the gut (van Es et al.,
2005; Wong et al., 2004). In the case of LSN-411575, it was
reported that a dose of 10 mg/kg administered for 15 days in
mice produced toxicity in the intestine and weight loss, whereas
a dose of 1 mg/kg had no detectable effects and the animals did
not lose weight (Wong et al., 2004). In our current study, mice
maintained their normal weight after 15 days of treatment with
3 mg/kg, suggesting the absence of deleterious side effects
(Figure S3D).
We obtained PET/CT scans of the same mice before and after
15 or 22 days of treatment (Figure 4A). Quantification of the size
of the tumors by CT (regardless of whether they were PET
positive or negative) revealed that the vehicle-treated tumors
increased in size (3.7-fold) after 15 days, whereas the LSN-
411575-treated ones grew significantly less than the vehicle-
treated controls (1.7-fold after 15 days and 1.2-fold after
22 days; Figure 4B). It is important to note that some of the
animals presented atelectasis, which prevents detection by
CT. Given the fact that CT cannot discriminate between nonma-
lignant and malignant tumors, we selectively focused on theresponse of PET-positive tumors (i.e. adenocarcinomas) and
quantified their total 18F-fluor-deoxyglucose (FDG) uptake pre-
and post-treatment. In the case of vehicle-treated mice, PET-
positive tumors increased their total FDG uptake an average of
2.2-fold during the 15 days of treatment (Figure 4C). In the
case of LSN-411575-treated mice, the average change was
0.7-fold after 15 days and 1.0-fold after 22 days (Figure 4C).
These results indicate that LSN-411575 has a significant inhibi-
tory effect on the growth of autochthonous murine KrasG12V-
driven NSCLCs.
Pharmacological Inhibition of g-Secretase Interferes
with ERK Phosphorylation in KrasG12V-Driven NSCLCs
Treated KrasG12V-driven NSCLCs (see Figure 4C) were analyzed
by IHC (samples were obtained 4–8 hr after the last treatment).
Our first goal was to evaluate whether the GSI treatment had
reached its target, and to that end we used the levels of HES1
as a surrogate marker of g-secretase activity. In accordance
with our previous observations (see Figure 1), the vehicle-treated
NSCLCs were strongly positive for HES1 (Figure 5A). In contrast,
NSCLCs treated with LSN-411575 for 15 days showed a clear
reduction in HES1 levels, confirming that the drug was actually
reaching its target within the tumors and at their natural localiza-
tion (Figure 5A). Also, in agreement with the robust increase in
FDG uptake observed during the 15-day interval (Figure 4C),
these tumors were highly proliferative (Ki67 staining) and had
a low level of apoptosis (activated caspase-3 staining; Figure 5A).
NSCLCs treated with LSN-411575 for 15 days presented
decreased levels of Ki67-positive cells and a higher frequency
of apoptotic cells compared with vehicle-treated tumors (Fig-
ure 5A). Of note, these tumors, except for their loss of mitotic
cells, retained all other histological features of grade 4 tumors
(characteristically defined by the presence of enlarged pleomor-
phic nuclei exhibiting a high degree of nuclear atypia and multi-
nucleated giant cells) (Jackson et al., 2005). These observations
strongly suggest that LSN-411575 arrests cancer growth by in-
hibiting proliferation and increasing apoptosis.
In an effort to understand the antitumoral effect of LSN-
411575, we explored a number of key players in lung cancer,
such as ERK (Engelman et al., 2008), AKT (Yang et al., 2008),
S6K (Liang et al., 2010), and NFkB (Meylan et al., 2009). In the
case of AKT (phospho-Ser473-AKT1), S6K (phospho-Thr389-
S6K1), andNFkB (nuclear p65), we could not find any differences
between NSCLCs treated for 15 days with vehicle or with LSN-
411575 (Figure S4A). However, we did find a remarkable effect
on the activity of ERK. In particular, vehicle-treated NSCLCs
were strongly positive for pERK1/pERK2 (phospho-Thr202/
Tyr204-ERK1 and phospho-Thr185/Tyr187-ERK2), whereas
LSN-411575-treated NSCLCs were significantly less positive
for pERK (Figure 5A). The results obtained by IHC were
confirmed by immunoblotting of tumor extracts. Specifically,
we observed lower levels of HES1 and pERK1/pERK2 in LSN-
411575-treated (15 days) NSCLCs compared with the corre-
sponding vehicle-treated tumors (Figures 5B and S4B). We
wondered whether the lower levels of pERK1/pERK2 were asso-
ciated with lower levels of its activating kinase, MEK; however,
the levels of pMEK1/2 (phospho-Ser217/Ser221-MEK1/2) re-
mained similar in vehicle- and LSN-411575-treated NSCLCs
(Figures 5B and S4B), suggesting that the inhibition of pERKCancer Cell 22, 222–234, August 14, 2012 ª2012 Elsevier Inc. 225
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Figure 4. Pharmacological Inhibition of g-
Secretase Arrests KrasG12V-Driven NSCLCs
(A) Representative examples of PET/CT analyses
of a single KrasG12V mouse at the beginning (pre)
and end (post) of 15 days of treatment with vehicle
(left) or LSN-411575 (right). Images correspond
to sagittal (left), coronal (middle), and transverse
(right) views. The positions of the PET-positive
tumor (t) and the heart (h) are labeled.
(B) Change in total tumor size detected by CT after
15 days of treatment with vehicle, and after 15 or
22 days of treatment with LSN-411575.
(C) Change in total 18F-FDG uptake of PET-
positive tumors after 15 days of treatment with
vehicle, and after 15 or 22 days of treatment with
LSN-411575.
Values correspond to the relative change of each
individual tumor from the day before initiation of
treatment to the last day of treatment. Bars cor-
respond to the average ± SEM. Top of graph: A
two-tailed Student’s t test (*p < 0.05; ***p < 0.001)
was used for statistical analysis.
See also Figure S3.
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g-Secretase and Lung Cancerexerted by LSN-411575 is independent of MEK activity. Finally,
we wanted to test whether the key observed changes in HES1
and pERKwere early events upon initiation of LSN-411575 treat-
ment. We treated mice for 4 days with LSN-411575, and found
that the levels of HES1 and pERK in NSCLCs were already lower
than in vehicle-treated tumors and similar to those observed in
tumors treated with the drug for 15 days (Figure 5C). Collectively,
these observations indicate that treatment with LSN-411575
arrests KrasG12V-driven NSCLCs in association with inhibition
of HES1 expression and ERK phosphorylation.
Inhibition of g-Secretase Increases DUSP1 in Human
and Murine Oncogenic-Kras NSCLCs
Previous investigators reported that the Notch pathway upregu-
lates pERK levels in cultured cells in vitro (Kim et al., 2005;
Konishi et al., 2007; Michie et al., 2007). However, the mecha-
nisms involved remained unexplored. In an effort to understand
the link between the Notch pathway and pERK in the context of
lung cancer cells, we focused on the human NSCLC cell line
H358, which carries an oncogenic KRAS allele (KRASG12C) and
requires the activity of the oncogene for its viability (Singh
et al., 2009). H358 cells were treated with the GSI DAPT, which
is a widely used GSI for assays with in vitro cultured cells (Wolfe,
2009). Recapitulating the results obtained in our lung mouse
model, DAPT-treated H358 cells also showed lower levels of
pERK (Figure 6A). We also explored two other human KRAS-226 Cancer Cell 22, 222–234, August 14, 2012 ª2012 Elsevier Inc.mutated NSCLC cell lines, namely, A549
and H23, which carry KRASG12S and
KRASG12C alleles, respectively (Blanco
et al., 2009), but whose growth is inde-
pendent of KRAS activity (Singh et al.,
2009). These cell lines also showed de-
creased levels of pERK upon DAPT treat-
ment (Figure S5A), but the magnitude of
the effect was not as pronounced as in
KRAS-dependent H358 cells.To gain insight into the mechanism by which inhibition of the
Notch pathway interferes with ERK phosphorylation, we per-
formed RNA microarray analyses to compare GSI-treated and
nontreated H358 cells (Table S1). As expected, among the genes
that were significantly downregulated by DAPT [false discovery
rate (FDR) p < 0.05; magnitude log2 fold change % 0.5-fold],
we identified HES1. Among the genes that showed significant
upregulation by DAPT (FDR p < 0.05;magnitude log2 fold change
R 0.5-fold), we noticed the dual-specificity phosphatases
DUSP1 and DUSP6, which are well-known negative regulators
of MAP kinases, including ERK (Patterson et al., 2009). Of
interest, DUSP1 is repressed by the Notch pathway in a NSCLC
cell line (Haruki et al., 2005); however, we are not aware of
a similar link for DUSP6. Validation by quantitative RT-PCR
(qRT-PCR) confirmed that both the DUSP1 and DUSP6 mRNAs
were upregulated after treatment of H358 cells with DAPT,
whereas HES1 mRNA levels were downregulated (Figure 6B
and Figure S5B). We confirmed that these changes in HES1
and DUSP1 mRNA levels correlated with similar changes in the
corresponding proteins (Figure 6C). In the case of A549 and
H23 cells, both showed a decrease in HES1 and an upregulation
of DUSP1 upon DAPT treatment; however, only A549 cells pre-
sented an upregulation of DUSP6 (Figures S5B and S5C). In an
effort to extrapolate these findings to a different type of Notch-
dependent cancer, we performed g-secretase inhibition of
a panel of human T-ALL cell lines. We observed DUSP1 mRNA
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Figure 5. Pharmacological Inhibition of
g-Secretase Diminishes HES1 and pERK in
KrasG12V-Driven NSCLCs
(A) IHC analyses of NSCLCs after 15 days of
treatment with vehicle or LSN-411575. Rows
correspond to serial sections of the same tumor.
Three examples of vehicle-treated tumors and
LSN-411575-treated tumors, each from a different
mouse, are shown. All pictures are at the same
magnification. The bar in the lower-right panel
corresponds to 100 mm. The quantifications shown
at the bottom correspond to all of the analyzed
NSCLCs: vehicle, 11 tumors (n = 11) present in 6
mice; LSN-411575, 12 tumors (n = 12) present in 6
mice. For each staining, two separate fields at 203
magnification were counted and an average of
1,500 cells were scored per tumor. Values corre-
spond to the average ± SEM. Statistical signifi-
cance was determined by a two-tailed Student’s
t test: *p < 0.05; **p < 0.01; ***p < 0.001.
(B) Immunoblotting of the indicated proteins in
PET-positive NSCLCs treated for 15 days with
vehicle or LSN-411575. Each lane corresponds to
a different tumor from a different mouse.
(C) Immunoblotting of the indicated proteins in
PET-positive NSCLCs treated with vehicle or LSN-
411575 for the indicated periods of time (4 days or
15 days). Each lane corresponds to a different
tumor from a different mouse.
See also Figure S4.
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g-Secretase and Lung Cancerupregulation in all of the cell lines, albeit of variable magnitude
(Figure S5D), whereas DUSP6 had an erratic behavior (Fig-
ure S5D). These results suggest that the upregulation of
DUSP1 is a general feature of g-secretase inhibition in cancer.
DUSP1 has been implicated in the dephosphorylation of ERK,
JNK, and p38 (Patterson et al., 2009). However, treatment with
DAPT resulted in reduced levels of pERK (see Figure 6A) but
did not affect the levels of phospho-JNK or phospho-p38 (Fig-
ure S5E). We wanted to confirm that DUSP1 was dephosphory-
lating pERK in our experimental system, and to that end,
we ectopically overexpressed a GFP-DUSP1 fusion (Wu et al.,
2005) and measured the levels of pERK by immunofluorescence
in the GFP-positive cells. Of interest, we observed that H358
cells expressing GFP-DUSP1 had very low levels of pERK
upon serum stimulation (10 min), whereas GFP control cells
had high levels of pERK under the same conditions (Figures 6D
and 6E). Again, we obtained similar results in A549 and H23 cellsCancer Cell 22, 222–234(Figure S5F). We then performed loss-of-
function studies. After testing a total of 12
different interfering RNAs (four siRNAs
and eight shRNAs) against DUSP1, we
observed only a rather modest effect
from combining two shRNAs (sh2+sh3;
Figure S5G). Despite the partial decrease
in DUSP1 levels, expression of the two
shRNAs (sh2+sh3) increased the levels
of pERK in transfected H358 compared
with a scrambled shRNA (shSC; Fig-
ure 6F). Moreover, expression of sh2+sh3
abolished the inhibitory effect of DAPTon pERK (Figure 6G), suggesting that the effects of DAPT on
pERK are mediated by DUSP1. We also wondered whether
DAPT treatment affected the levels of pMEK in H358 cells. We
did not observe any changes in pMEK induced by DAPT (Fig-
ure S5H), in agreement with our previous observations in GSI-
treated tumors (Figures 5B and S4B). These results support
the concept that GSI treatment inhibits KRAS signaling through
DUSP1 by decreasing the levels of pERK, and without affecting
the activity of MEK.
To validate the above data in vivo, we compared the levels of
Dusp1 and Dusp6 mRNAs in primary murine KrasG12V-driven
NSCLCs treated for 15 days with LSN-411575 or with vehicle.
Of importance, adenocarcinomas from mice treated with LSN-
411575 presented increased levels of Dusp1/DUSP1 (Figures
6H and 6I) and decreased levels of Hes1/HES1 (Figures 5B
and 6H) mRNA and protein compared with vehicle-treated
adenocarcinomas. In contrast, we did not observe any changes, August 14, 2012 ª2012 Elsevier Inc. 227
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Figure 6. Inhibition of g-Secretase Increases
DUSP1 in Human and Mouse NSCLCs
(A) Analysis of pERK in H358 cells treated with 5 mMDAPT
or with vehicle. Cells were treated for 48 hr (36 hr in the
presence of serum and then 12 hr in the absence of serum)
and then stimulated with serum for the indicated times (in
minutes).
(B) Analysis of DUSP1 and HES1 expression by qRT-PCR
in nontreated (vehicle, n = 3) or DAPT-treated (5 mMDAPT,
n = 3) H358 cells. Cells were treated for 48 hr (36 hr in the
presence of serum and then 12 hr in the absence of
serum).
(C) Analysis of HES1 and DUSP1 in H358 cells treated with
5 mM DAPT or with vehicle. Cells were treated for 48 hr
(36 hr in the presence of serum and then 12 hr in the
absence of serum) and then stimulated with serum for the
indicated times (in minutes).
(D) Fluorescence detection of GFP and phospho-ERK in
H358 cells transfected with GFP alone or with a GFP-
DUSP1 fusion. Cells were starved and serum stimulated
for 10 min. GFP-positive cells are marked with a white line.
All images are at the same magnification. The bar in the
lower right panel corresponds to 20 mm.
(E) Quantification of the experiment shown in (D). GFP-
positive cells (n = 75) were quantified with an automatic
software for each transfection (GFPalone, orGFP-DUSP1).
(F) Fluorescence detection of GFP and quantification of
phospho-ERK in H358 cells transfected with pGIPZ
scramble (shSC), with pGIPZ anti-DUSP1 shRNAs (sh2,
sh3, and sh2+sh3). Thirty-six hours after transfection, cells
were starved for 12 hr and then serum stimulated for
10 min. GFP-positive cells (n = 120) were quantified with
automatic software for each transfection.
(G) Cells were transfected as in (F), and 6 hr after trans-
fection the cells were treated with vehicle or with DAPT
(5 mM) for 48 hr (36 hr in the presence of serum and then
12 hr in the absence of serum) and then stimulated with
serum for 10 min. GFP-positive cells (n = 120) were
quantified with automatic software for each transfection.
(H) Analysis ofHes1 and Dusp1 expression by qRT-PCR in
PET-positive KrasG12V-driven NSCLCs treated with LSN-
411575 (n = 4) or vehicle (n = 4) for 15 days.
(I) Immunoblotting of the indicated proteins in PET-posi-
tive KrasG12V-driven NSCLCs treated for 15 days with
vehicle or LSN-411575. Each lane corresponds to
a different adenocarcinoma from a different mouse. These
adenocarcinomas are the same ones analyzed in Fig-
ure 5B and were loaded in the same order.
Values correspond to the average ± SEM. Statistical
significance was determined by a two-tailed Student’s
t test: *p < 0.05; ***p < 0.001.
See also Figure S5 and Table S1.
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g-Secretase and Lung CancerinDusp6 (Figure S5I). Taken together, these data establish a tight
association between HES1 downregulation and DUSP1 induc-
tion upon GSI treatment in cancer.
HES1 Directly Binds and Represses the DUSP1
Promoter
The transcriptional repressor HES1 is a critical mediator of
NOTCH1-driven cancer (Wendorff et al., 2010). On the basis of
this finding and our above data, we hypothesized that HES1
can repressDUSP1. To explore this possibility, we began by per-
forming DUSP1 promoter assays using a luciferase reporter. Of
note, treatment of H358 cells with DAPT induced the DUSP1228 Cancer Cell 22, 222–234, August 14, 2012 ª2012 Elsevier Inc.promoter, and this was canceled when HES1 was cotransfected
(Figure 7A). These results further reinforce our previous obser-
vations that g-secretase inhibition upregulates the expression
of DUSP1 by downregulating HES1. Additionally, the basal
activity of theDUSP1 promoter was decreased by HES1 expres-
sion (Figures 7A and 7B). Also, as a marginal note, treatment
of cells with a pharmacological MEK inhibitor (PD0325901)
decreased the activity of the DUSP1 promoter (Figure 7B), in
accordance with the known role of MEK as a positive regulator
of DUSP1 expression (Brondello et al., 1997), again suggesting
that g-secretase inhibition exerts its actions in a MEK-indepen-
dent manner.
A B
C
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F G
Figure 7. HES1 Directly Binds and Represses the DUSP1 Promoter
(A) Luciferase activity of H358 cells transfected with a DUSP1-luc reporter
together with a plasmid expressing HES1 or its corresponding empty control.
Cells were treated for 48 hr with 5 mM DAPT or its vehicle in the presence of
complete medium.
(B) Luciferase activity of H358 cells transfected with a DUSP1-luc reporter
together with a plasmid expressing HES1 or its corresponding empty control.
Cells were treated for 48 hr with a MEK inhibitor (PD0325901) or its vehicle in
the presence of complete medium.
(C) ChIP analysis of the DUSP1 promoter using two different HES1 antibodies
[Ab1, 4H1 (Novus Biologicals) and Ab2, H140 (Santa Cruz Biotechnology)] in
H358 cells. Four different DNA regions were analyzed by qPCR: two from the
DUSP1 promoter (see Figure S5), an intronic region fromDUSP1 (intron 3), and
the promoter of DELTEX1. Cells were treated with 5 mM DAPT or vehicle
(ETOH) for 48 hr. Data correspond to three independent biological replicates.
(D) Levels of HES1 and DUSP1 expression measured by qRT-PCR in H358
cells treated with siHES1 (HES1 siRNA, n = 3) or nontargeting siRNA (siNT,
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DUSP1 promoter, we sought to determine whether HES1
directly binds to the DUSP1 promoter. HES1 binds two similar
sequence motifs, known as class C sites and N-boxes (Iso
et al., 2003), and an examination of the human and murine
DUSP1/Dusp1 promoters revealed the presence of several
putative HES1 binding sites (Figure S6). We tested whether
HES1 directly binds to the human DUSP1 promoter by chro-
matin immunoprecipitation (ChIP) using two different anti-
bodies against HES1 in H358 cells. Of interest, HES1 immuno-
precipitation with two different antibodies resulted in significant
enrichment of two regions of the DUSP1 promoter compared
with a control IgG immunoprecipitation (Figure 7C). In contrast,
no enrichment was observed when a DUSP1 intronic region
was amplified or when cells were treated with DAPT (Fig-
ure 7C). As a positive control, we used the DELTEX1 promoter,
which is directly repressed by HES1 (Zhang et al., 2010). As
expected, binding of HES1 to the DELTEX1 promoter was
observed in the absence of DAPT, but not in its presence
(Figure 7C).
We wanted to test the effect of HES1 inhibition on DUSP1
levels and ERK phosphorylation. Treatment of H358 cells with
a pool of siRNAs targeting HES1 mRNA (siHES1) effectively
reduced HES1 mRNA and protein levels (Figures 7D and 7E),
and, of importance, this resulted in significant upregulation of
DUSP1 mRNA and protein levels (Figures 7D and 7E). We pre-
viously demonstrated that DUSP1 dephosphorylates pERK
(Figures 6D and 6E), and in agreement with this, siHES1 reduced
the levels of phosphorylated ERK (Figures 7E and 7F). Finally,
previous reports showed that GSIs can prevent the growth of
human cancer cell lines (Chen et al., 2007; Eliasz et al., 2010;
Westhoff et al., 2009), and we wondered whether this could
also be the case for siHES1. Indeed, cells treated with siHES1
had an impaired proliferative capacity (Figure 7G). All together,
these findings show that inhibition of HES1 in NSCLCs cells
recapitulates the effect of DAPT treatment on DUSP1 expres-
sion, ERK phosphorylation, and cell proliferation.
High HES1 and Low DUSP1 Levels Are Associated with
Poor Clinical Outcome in Patients with NSCLC
Previous investigators reported that subsets of patients with
NSCLC have a hyperactivated Notch pathway (Haruki et al.,
2005; Westhoff et al., 2009), which correlates with a poor clinical
outcome (Westhoff et al., 2009). In the light of our above results,
we wanted to extend this observation to HES1 and examine its
relation to DUSP1. We examined the levels of HES1 in a seriesn = 3) for 48 hr (36 hr in the presence of serum and then 12 hr in the absence of
serum).
(E) Protein levels of DUSP1, HES1, pERK, and total ERK in H358 cells treated
as in (D).
(F) Phosphorylation of ERK in H358 cells treated with siHES1 (HES1 siRNA) or
siNT for 48 hr (36 hr in the presence of serum and then 12 hr in the absence of
serum) and then stimulated with serum for the indicated times (in minutes).
(G) H358 cells were treatedwith siHES1 (HES1 siRNA, n = 3) or siNT (n = 3), and
cell numbers were counted at the indicated time points after siRNA trans-
fection.
Values correspond to the average ± SEM. Statistical significance was deter-
mined by a two-tailed Student’s t test: #p < 0.1; *p < 0.05; **p < 0.01.
See also Figure S6.
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Figure 8. High HES1 and Low DUSP1 Levels Are Associated with
Poor Clinical Outcome in Primary Human NSCLCs
(A) Kaplan-Meier curve indicating that patients with NSCLCs with high
expression of nuclear HES1 present shorter overall survival (p = 0.045). High
nuclear HES1 expression corresponds to tumors in which at least 40% of their
neoplastic cells are positive for HES1.
(B) Kaplan-Meier curve indicating that patients with NSCLCs with low
expression of cytoplasmic DUSP1 present poorer overall survival (p = 0.048).
Low cytoplasmic DUSP1 expression corresponds to tumors in which <70% of
their neoplastic cells are positive for DUSP1.
(C) Summary of the data presented in this work. See Discussion for a detailed
explanation.
A logrank test was used to determine statistical significance.
See also Figure S7.
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g-Secretase and Lung Cancerof NSCLCs (n = 82), and observed that tumors with high levels
of nuclear HES1 were associated with a shorter overall sur-
vival (logrank, p = 0.045; Figure 8A and Figure S7A). Previous
investigators found a positive correlation between DUSP1 levels
and survival in human NSCLCs (Vicent et al., 2004). We
confirmed this result in our NSCLC series, in which we obtained
a positive correlation between DUSP1 cytoplasmic expression
and better overall survival (logrank, p = 0.048; Figure 8B and Fig-
ure S7A). Moreover, when patients were stratified according to
HES1 and DUSP1, those who showed a combination of high
HES1 intensity and low DUSP1 expression had the poorest
outcome compared with the other three possible combinations
(logrank test, p = 0.09; Figure S7B). Finally, there was a negative
correlation between HES1 intensity and DUSP1 expression
(correlation coefficient 0.219; Kendall Tau-b test, p = 0.07).
Collectively, these observations support the relevance of HES1
in human NSCLCs and reinforce the concept that HES1 re-
presses DUSP1.230 Cancer Cell 22, 222–234, August 14, 2012 ª2012 Elsevier Inc.DISCUSSION
In this work, we investigated the role of the Notch pathway in
the generation and maintenance of primary KrasG12V-driven
NSCLCs.
Previous studies showed that a significant proportion of
patients with NSCLC have a hyperactive Notch pathway (Haruki
et al., 2005; Westhoff et al., 2009), but did not examine the role of
the Notch pathway in the development of NSCLCs. To address
this question, we used a mouse model with a latent Kras onco-
gene that faithfully recapitulates the development of human
NSCLCs (Guerra et al., 2003; Jackson et al., 2001; Sweet-
Cordero et al., 2005). First, we validated our mouse model by
observing that, as in humans, the Notch pathway is hyperactive
in murine KrasG12V-driven NSCLCs compared with normal lung.
This is evidenced by higher levels of active g-secretase complex,
increased levels of NICD (the activated form of NOTCH1),
decreased Numb mRNA (a negative regulator of the Notch
pathway), and increased HES1 protein (a downstream target of
the Notch pathway). HES1 protein levels increased in parallel
with the degree of malignization, suggesting a requirement of
Notch pathway activity during this process. Of note, genetic
elimination of either the g-secretase complex (upstream of the
Notch pathway) or Rbpj (encoding the canonical DNA-binding
partner of NICDs) abolished the formation of KrasG12V-driven
NSCLCs. These results indicate that the generation of NSCLCs
by oncogenic Kras requires the activation of the Notch pathway.
On the basis of the above findings, we hypothesized that
Notch activity may also be required for the maintenance of
primary KrasG12V-driven NSCLCs. Previous reports in this direc-
tion showed that g-secretase inhibition slows the growth of
subcutaneous xenografts formed by lung cancer cells (Konishi
et al., 2007; Luistro et al., 2009; Paris et al., 2005). Xenografts,
despite their utility, do not recapitulate the microenvironment
of the natural primary tumors, and this may have a critical impact
on therapeutic activity, as was elegantly illustrated in the case of
pancreatic cancer (Olive et al., 2009). Only a handful of studies
have evaluated the efficacy of chemotherapy for primary murine
lung tumors (Engelman et al., 2008; Ji et al., 2007; Yang
et al., 2008). These studies were largely based on MRI or CT,
which cannot discriminate nonmalignant tumors from malignant
ones. Here, in an effort to recapitulate a human clinical setting,
we also evaluated therapeutic responses by using PET, thus
focusing exclusively on malignant tumors. Of importance, mice
treated with the pharmacologically active GSI LSN-411575
showed a complete blockade of cancer growth. These results
demonstrate that GSIs are therapeutically effective for primary
autochthonous KrasG12V-driven NSCLCs in mice.
Analyses of LSN-411575-treated, KrasG12V-driven NSCLCs
indicated a significant reduction in the levels of HES1 as soon
as 4 days after treatment, thus confirming that the GSI reached
its target. In addition, treated NSCLCs presented decreased
proliferation and increased apoptosis. Among a number of key
candidate proteins that could be affected by GSI treatment, we
selectively detected an effect on the phosphorylation of ERK,
which was dramatically reduced after treatment. This obser-
vation is in accordance with previous data obtained in in vitro
cultured cells, which showed that the Notch pathway upregu-
lates the levels of ERK phosphorylation (Kim et al., 2005; Konishi
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g-Secretase and Lung Canceret al., 2007; Michie et al., 2007). The role of ERK phosphorylation
in Kras-driven NSCLCs was recently highlighted by the demon-
stration that ERK activity is essential for Kras-driven lung tumor-
igenesis (Blasco et al., 2011; Feldser et al., 2010; Junttila et al.,
2010). Because MEK is the critical kinase responsible for ERK
phosphorylation, we also examined the levels of phosphorylated
MEK in GSI-treated NSCLCs; however, in contrast to phospho-
ERK, the levels of phospho-MEKwere not affected by the GSI. In
summary, we found that GSI treatment of primary autochtho-
nous KrasG12V-driven NSCLCs impinges on the phosphorylation
of ERK without affecting MEK activity.
To dissect the mechanism that links g-secretase inhibition
with dephosphorylation of ERK, we analyzed the transcriptional
changes induced by GSI. In particular, we used a human NSCLC
cell line, H358, which is addicted to oncogenic KRAS (Singh
et al., 2009). These cells, as we have shown here, dephosphor-
ylate ERK in response to GSI treatment without affecting
phospho-MEK, thus recapitulating the behavior of primary
KrasG12V-driven NSCLCs. Among the set of genes whose ex-
pression was induced by GSI treatment, we focused our atten-
tion on the dual-specificity phosphatase DUSP1 because
previous data obtained in human NSCLC cells indicate that
this phosphatase is regulated by the Notch pathway (Haruki
et al., 2005) and dephosphorylates ERK (Lin et al., 2003; Patter-
son et al., 2009). Indeed, using both gain- and loss-of-function
experiments, we confirmed the concept that DUSP1 affects
ERK phosphorylation in human H358 cells. Moreover, the induc-
tion of DUSP1 after GSI treatment was confirmed in another two
human NSCLC cell lines and in six human T-ALL cell lines, thus
giving more general validity to our findings. Finally, we observed
Dusp1 upregulation in GSI-treated murine primary KrasG12V-
driven NSCLCs. Therefore, the observed association between
GSI treatment and DUSP1 upregulation occurs in the context
of primary NSCLCs, and could explain the reduction in ERK
phosphorylation upon GSI treatment.
HES1 is a well known transcriptional repressor of multiple
genes (Iso et al., 2003; Sang et al., 2010), including genes that
are relevant for T-ALL, such as PTEN (Palomero et al., 2007)
and CYLD (Espinosa et al., 2010), which activate AKT and
NFkB, respectively. Furthermore, it was recently demonstrated
that HES1 plays a critical role in the maintenance of NOTCH1-
driven murine T-ALL (Wendorff et al., 2010). Based on our obser-
vation that HES1 levels increase in associationwithmalignization
and decrease upon GSI treatment of KrasG12V-driven NSCLCs,
we hypothesized that GSI-induced dephosphorylation of ERK
could be mediated by HES1-mediated repression of DUSP1.
Indeed, luciferase reporter assays supported the concept that
HES1 is a negative regulator of DUSP1. Furthermore, ChIP
showed that HES1 directly binds to and represses DUSP1, and
that this process can be reverted by GSI treatment. In addition,
treatment of H358 cells with siHES1 promoted a phenotype
very similar to that obtained by GSI treatment in terms of ERK
phosphorylation, DUSP1 upregulation, and cell growth arrest.
Finally, we checked the status of HES1 and DUSP1 in primary
human NSCLCs. We found that low DUSP1 is associated with
poor survival, which is in agreement with previous data (Vicent
et al., 2004). In support of our proposed mechanism, we found
that high HES1 levels are also associated with poor survival.
Moreover, we also observed a suggestive negative correlationbetween HES1 intensity and DUSP1 expression. These ob-
servations support the relevance of HES1 in human NSCLCs
and reinforce the concept that HES1 represses DUSP1.
Collectively, our observations establish a direct causal link
among g-secretase inhibition, HES1 downregulation, DUSP1
derepression, and ERK dephosphorylation (Figure 8C). As
mentioned above, high ERK activity is crucial for the develop-
ment of Kras-driven NSCLCs (Blasco et al., 2011; Feldser
et al., 2010; Junttila et al., 2010), and, in this regard, we propose
that our observation that the Notch pathway is required for
NSCLC formation is related to the capacity of HES1 to increase
ERK activity through repression of Dusp1. Although our current
data point to HES1 and DUSP1 as relevant mediators of the
effects of GSI treatment on the KRAS signaling pathway, we
cannot exclude the possibility that other members of the HES1
family or DUSP1 family, or other unrelated mechanisms, may
also participate in mediating the effects of GSI treatment.
The results presented in this work support the therapeutic
potential of targeting g-secretase in NSCLC. We show that GSI
treatment inhibits ERK without affecting MEK, and hence we
envision a synergistic effect of MEK inhibitors and GSIs on
KRAS-driven NSCLCs. Of importance, GSIs have been shown
to be pharmacologically active in humans (Bateman et al.,
2009) and have been tested in clinical trials for Alzheimer disease
(Fleisher et al., 2008; Panza et al., 2009; Wolfe, 2009), which
could facilitate the evaluation of these compounds for the treat-
ment of human lung cancer, the leading cause of cancer-related
deaths in the world.EXPERIMENTAL PROCEDURES
Mice
Mice were generated by crossing Kras+/LSLG12Vgeo mice (Guerra et al., 2003)
with Psen1f/f;Psen2/ (Saura et al., 2004) or Rbpjf/f (Tanigaki et al., 2002)
mice. All animal procedures were performed according to protocols approved
by the National Cancer Research Center-Instituto de Salud Carlos III (CNIO-
ISCIII) Ethics Committee for Research and Animal Welfare.
DNA, RNA, and Protein Analyses
Details regarding the PCR primers, antibodies, and other standard molecular
biology methods used in this work are provided in Supplemental Experimental
Procedures.
Micro-PET/CT
Imaging was done essentially as described previously (Mulero et al., 2011).
See the summary in Supplemental Experimental Procedures.
Treatment with LSN-411575
The LSN-411575 compound was kindly provided by Eli Lilly and Company and
formulated in 1% carboxymethyl cellulose, 0.25% Tween 80. The compound
was given orally by gavage early in the morning, at a dose of 3 mg/kg/day
for the indicated number of days. Control mice were treated with the vehicle
following an identical procedure. On the last day of treatment, PET was
performed within 2–6 hr after gavage (vehicle- and compound-treated mice
were in alternate order for the analysis). Mice were killed within 4–8 hr after
gavage, and samples were obtained for pathological and IHC analyses.
Cellular Treatments
H358 humanNSCLC cells were purchased fromATCC. Cells were treatedwith
5 mM DAPT (Calbiochem) for 36 hr in the presence of serum. The cells were
then serum starved for 12 hr in the presence of DAPT or vehicle, as indicated
in the corresponding figures. When noted, cells were serum stimulated for theCancer Cell 22, 222–234, August 14, 2012 ª2012 Elsevier Inc. 231
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g-Secretase and Lung Cancerindicated time. For additional details, see Supplemental Experimental
Procedures.
Human Samples
Primary lung tumorswere collected and handled anonymously at collaborating
institutions (Instituto Angel H. Roffo andHospital Britanico) with the approval of
their institutional review boards and following standard ethical and legal
protection guidelines regarding human subjects, including informed consent.
Statistical Analysis
Unless otherwise specified, data are presented as mean ± SEM. Student’s
t test was used to assess the significance of expression levels by both qRT-
PCR and IHC. Student’s t test was also used to determine the differences
among groups for changes in tumor size or animal weight. Associations of
protein expression patterns in human TMA of HES1 and DUSP1 were evalu-
ated using the Kendall tau test. Survival curves were tested by logrank test.
ACCESSION NUMBERS
Microarray data were deposited in the National Center for Biotechnology Infor-
mation’s Gene Expression Omnibus (accession number GSE38054).
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2012.06.014.
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